CuraGen Corp. and TopoTarget have initiated patient dosing in a Phase II trial evaluating the antitumor activity of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of ovarian cancer. The National Cancer Institute (NCI) is sponsoring this trial through an agreement with CuraGen for PXD101. The Phase II trial is an open-label study of patients with either advanced platinum resistant ovarian tumors or micropapillary/borderline low malignant potentia...